Since glycometabolism-related risk scores were associated with poor prognosis in HCC, we explored the relationship between risk scores and resistance to ICI (PD-1 and CTLA-4) and targeted drugs (sorafenib and 5-fluorouracil). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.